PDS BIOTECHNOLOGY (PDSB) Refocuses on IL-12 Asset After Nant Capital Financing
Corporate deck filed with the SEC shows a 71.4% six-month response rate for PDS0301 in liver-metastatic colorectal cancer and a new board seat for Patrick Soon-Shiong.
PDS Biotechnology (PDSB) filed an investor presentation with the SEC on September 21 that lays out a strategic refocus on PDS0301, its tumor-targeted IL-12 immunocytokine, following a September 2026 financing led by Nant Capital. The company says it is now seeking a strategic partnership or external funding for its other lead asset, the Versamune HPV16 cancer vaccine PDS0101, rather than funding further development itself.